Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SYNLOGIC, INC.SYBX · Entity 7801 | Director | June 22, 2023 | June 26, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SYNLOGIC, INC.
Report date June 22, 2023 · Filed June 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-06-22 | Direct | 30,000 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
2seventy bio, Inc.
Report date May 13, 2025 · Filed May 15, 2025
Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-05-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-13 · Disposition to issuer · Disposed 335,964 · Balance 897,642 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Row 2 · 2025-05-13 · Other · Disposed 897,642 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. |
| Common StockSEC Table I · non-derivative | IndirectNick Leschly 2001 Trust | 0 |
Reported balance
After 2025-05-13 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-05-13 · Other · Disposed 15,233 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. |
| Common StockSEC Table I · non-derivative | IndirectNick Leschly Irrevocable GST Trust of 2019 | 0 |
Reported balance
After 2025-05-13 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2025-05-13 · Other · Disposed 41,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.97 | Direct | 0 |
Reported balance
After 2025-05-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-05-13 · Disposition to issuer · Disposed 469,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.
F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration.
bluebird bio, Inc.
Report date May 30, 2025 · Filed June 03, 2025
Section 16 reporting ended · disclosed 2025-06-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-06-02 transaction · row 4
2 source rows · reconciled sequenceRow 1 · 2025-05-30 · Other · Disposed 14,416 · Balance 1,245 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Row 4 · 2025-06-02 · Disposition to issuer · Disposed 1,245 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F4: (Continued from footnote 1) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time. |
| Common StockSEC Table I · non-derivative | IndirectNick Leschly 2001 Trust | 0 |
Reported balance
After 2025-05-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-05-30 · Other · Disposed 2,284 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. |
| Common StockSEC Table I · non-derivative | IndirectNick Leschly Irrevocable GST Trust of 2019 | 0 |
Reported balance
After 2025-05-30 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-05-30 · Other · Disposed 6,150 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price").
F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive
F4: (Continued from footnote 1) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 11, 2021 Filed Nov 16, 2021 06:43 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 33,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023470 · wf-form4_163706292470660.xml · nonDerivative · entry 5 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,191 F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP"), the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date (the "2seventy VWAP") multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: The number of shares underlying the converted 2seventy equity awards was determined by multiplying the number of shares underlying the existing bluebird equity awards by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the sum of (1) the 2seventy VWAP multiplied by the distribution ratio and (2) the quotient obtained by dividing the bluebird Post-Distribution VWAP by the distribution ratio. bluebird equity awards granted on or after January 1, 2021, such equity awards were converted into 2seventy equity awards. The number of shares of 2seventy common stock underlying such converted equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the 2seventy VWAP. F7 · security: In connection with the Separation, the reporting person received a grant of restricted stock units, each representing the right to receive a share of 2seventy's common stock, as a result of the adjustment of existing bluebird restricted stock units prior to the Separation (see footnotes 2 and 3). This restricted stock unit award vests over a two-year period at the rate of 40% on 08/02/2022 and 60% on 08/02/2023. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:43 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 11,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023470 · wf-form4_163706292470660.xml · nonDerivative · entry 4 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,153 F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP"), the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date (the "2seventy VWAP") multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: The number of shares underlying the converted 2seventy equity awards was determined by multiplying the number of shares underlying the existing bluebird equity awards by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the sum of (1) the 2seventy VWAP multiplied by the distribution ratio and (2) the quotient obtained by dividing the bluebird Post-Distribution VWAP by the distribution ratio. bluebird equity awards granted on or after January 1, 2021, such equity awards were converted into 2seventy equity awards. The number of shares of 2seventy common stock underlying such converted equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the 2seventy VWAP. F6 · security: In connection with the Separation, the reporting person received a grant of restricted stock units, each representing the right to receive a share of 2seventy's common stock, as a result of the adjustment of existing bluebird restricted stock units prior to the Separation (see footnotes 2 and 3). This restricted stock unit award vests over a four-year period at the rate of 25% on 01/04/2022, 25% on 01/04/2023, 25% on 01/04/2024, and 25% on 01/04/2025. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:43 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 7,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023470 · wf-form4_163706292470660.xml · nonDerivative · entry 3 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,562 F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP"), the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date (the "2seventy VWAP") multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: The number of shares underlying the converted 2seventy equity awards was determined by multiplying the number of shares underlying the existing bluebird equity awards by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the sum of (1) the 2seventy VWAP multiplied by the distribution ratio and (2) the quotient obtained by dividing the bluebird Post-Distribution VWAP by the distribution ratio. bluebird equity awards granted on or after January 1, 2021, such equity awards were converted into 2seventy equity awards. The number of shares of 2seventy common stock underlying such converted equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the 2seventy VWAP. F5 · security: In connection with the Separation, the reporting person received a grant of restricted stock units, each representing the right to receive a share of 2seventy's common stock, as a result of the adjustment of existing bluebird restricted stock units prior to the Separation (see footnotes 2 and 3). This restricted stock unit award vests over a four-year period at the rate of 25% on 01/04/2021, 25% on 01/04/2022, 25% on 01/04/2023, and 25% on 01/04/2024. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:43 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 4,102 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023470 · wf-form4_163706292470660.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,563 F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP"), the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date (the "2seventy VWAP") multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: The number of shares underlying the converted 2seventy equity awards was determined by multiplying the number of shares underlying the existing bluebird equity awards by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the sum of (1) the 2seventy VWAP multiplied by the distribution ratio and (2) the quotient obtained by dividing the bluebird Post-Distribution VWAP by the distribution ratio. bluebird equity awards granted on or after January 1, 2021, such equity awards were converted into 2seventy equity awards. The number of shares of 2seventy common stock underlying such converted equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the 2seventy VWAP. F4 · security: In connection with the Separation, the reporting person received a grant of restricted stock units, each representing the right to receive a share of 2seventy's common stock, as a result of the adjustment of existing bluebird restricted stock units prior to the Separation (see footnotes 2 and 3). This restricted stock unit award vests over a four-year period at a rate of 25% on 01/04/2020, 25% on 01/04/2021, 25% on 01/04/2022, and 25% on 01/04/2023 . Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:43 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 2,461 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023470 · wf-form4_163706292470660.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,461 F1 · security: In connection with the separation (the "Separation") of seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"), the reporting person received restricted stock units, each representing the right to receive a share of 2seventy's common stock, as a result of the adjustment of existing bluebird restricted stock units prior to the Separation (see footnote 16). This restricted stock unit award vests over a four-year period at a rate of 25% on 01/04/2019, 25% on 01/04/2020, 25% on 01/04/2021, and 25% on 01/04/2022. F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP"), the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date (the "2seventy VWAP") multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: The number of shares underlying the converted 2seventy equity awards was determined by multiplying the number of shares underlying the existing bluebird equity awards by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the sum of (1) the 2seventy VWAP multiplied by the distribution ratio and (2) the quotient obtained by dividing the bluebird Post-Distribution VWAP by the distribution ratio. bluebird equity awards granted on or after January 1, 2021, such equity awards were converted into 2seventy equity awards. The number of shares of 2seventy common stock underlying such converted equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the 2seventy VWAP. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Disposition to issuerStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023648 · wf-form4_163715739431374.xml · derivative · entry 17 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2031-02-16 F18 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on February 16, 2021 and vests over a four-year period, at a rate of 25% on 01/04/2022 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F18 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on February 16, 2021 and vests over a four-year period, at a rate of 25% on 01/04/2022 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F18 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on February 16, 2021 and vests over a four-year period, at a rate of 25% on 01/04/2022 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Disposition to issuerStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $36.78 | $0.00 |
DisclosureSEC source: 0001628280-21-023648 · wf-form4_163715739431374.xml · derivative · entry 16 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,995 Underlying: Common Stock · 63,995 shares Expires 2030-03-02 F17 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on March 2, 2020 and vests over a four-year period, at a rate of 25% on 01/04/2021 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F17 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on March 2, 2020 and vests over a four-year period, at a rate of 25% on 01/04/2021 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F17 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on March 2, 2020 and vests over a four-year period, at a rate of 25% on 01/04/2021 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Disposition to issuerCommon Stock · Derivative | 100,000 | $0.00 Strike: $67.06 | $0.00 |
DisclosureSEC source: 0001628280-21-023648 · wf-form4_163715739431374.xml · derivative · entry 15 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,454 Underlying: Common Stock · 98,454 shares Expires 2029-02-01 F16 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on February 1, 2019 and vests over a four-year period, at a rate of 25% on 01/04/2020 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F16 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on February 1, 2019 and vests over a four-year period, at a rate of 25% on 01/04/2020 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F16 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on February 1, 2019 and vests over a four-year period, at a rate of 25% on 01/04/2020 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Disposition to issuerStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $102.24 | $0.00 |
DisclosureSEC source: 0001628280-21-023648 · wf-form4_163715739431374.xml · derivative · entry 14 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,145 Underlying: Common Stock · 118,145 shares Expires 2028-02-01 F15 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on February 1, 2018 and vests over a four-year period, at a rate of 25% on 01/04/2019 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F15 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on February 1, 2018 and vests over a four-year period, at a rate of 25% on 01/04/2019 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F15 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on February 1, 2018 and vests over a four-year period, at a rate of 25% on 01/04/2019 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Disposition to issuerStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $37.66 | $0.00 |
DisclosureSEC source: 0001628280-21-023648 · wf-form4_163715739431374.xml · derivative · entry 13 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,300 Underlying: Common Stock · 108,300 shares Expires 2027-02-01 F14 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on February 1, 2017 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F14 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on February 1, 2017 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F14 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on February 1, 2017 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Disposition to issuerStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $25.16 | $0.00 |
DisclosureSEC source: 0001628280-21-023648 · wf-form4_163715739431374.xml · derivative · entry 12 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,609 Underlying: Common Stock · 88,609 shares Expires 2026-03-01 F13 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on March 1, 2016 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F13 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on March 1, 2016 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F13 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on March 1, 2016 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Disposition to issuerStock Option (right to buy) · Derivative | 165,000 | $0.00 Strike: $48.52 | $0.00 |
DisclosureSEC source: 0001628280-21-023648 · wf-form4_163715739431374.xml · derivative · entry 11 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,450 Underlying: Common Stock · 162,450 shares Expires 2025-03-02 F12 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on March 2, 2015 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F12 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on March 2, 2015 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F12 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on March 2, 2015 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Disposition to issuerStock Option (right to buy) · Derivative | 165,000 | $0.00 Strike: $12.19 | $0.00 |
DisclosureSEC source: 0001628280-21-023648 · wf-form4_163715739431374.xml · derivative · entry 10 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,450 Underlying: Common Stock · 162,450 shares Expires 2024-03-03 F11 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on March 3, 2014 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F11 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on March 3, 2014 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F11 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on March 3, 2014 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023648 · wf-form4_163715739431374.xml · nonDerivative · entry 7 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,767 F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. F9 · security: Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on August 2, 2021 and vests upon the satisfaction of certain performance criteria. F10 · balance_after: 762 shares were acquired under the bluebird bio, Inc. employee stock purchase plan. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023648 · wf-form4_163715739431374.xml · nonDerivative · entry 6 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,005 F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. F8 · security: Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on August 2, 2021 and vests over a two-year period at the rate of 40% on August 2, 2022 and 60% on August 2, 2023. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023648 · wf-form4_163715739431374.xml · nonDerivative · entry 5 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,005 F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. F7 · security: Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on February 16, 2021 and vests over a four-year period at a rate of 25% on 01/04/2022, 25% on 01/04/2023, 25% on 01/04/2024, and 25% on 01/04/2025. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023648 · wf-form4_163715739431374.xml · nonDerivative · entry 4 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,005 F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. F6 · security: Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award vests upon the satisfaction of certain performance criteria. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 23,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023648 · wf-form4_163715739431374.xml · nonDerivative · entry 3 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,005 F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. F5 · security: Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on March 2, 2020 and vests over a four-year period at the rate of 25% on 01/04/2021, 25% on 01/04/2022, 25% on 01/04/2023, and 25% on 01/04/2024. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 12,306 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023648 · wf-form4_163715739431374.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,007 F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. F4 · security: Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on February 1, 2019 and vests over a four-year period at a rate of 25% on 01/04/2020, 25% on 01/04/2021, 25% on 01/04/2022, and 25% on 01/04/2023. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:56 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 7,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023648 · wf-form4_163715739431374.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,701 F1 · security: Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on February 1, 2018 and vests over a four-year period at a rate of 25% on 01/04/2019, 25% on 01/04/2020, 25% on 01/04/2021, and 25% on 01/04/2022. F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 16:53 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 51,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-005173 · primarydocument.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,299 F2 · security: Restricted stock unit awards shall vest upon the satisfaction of certain performance criteria. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 16:53 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 51,304 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-005173 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,996 F1 · security: Restricted stock unit awards vest over a two-year period at the rate of 40% on August 2, 2022 and 60% on August 2, 2023. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:12 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0000899243-21-023614 · doc4.xml · derivative · entry 1 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. Read SEC document |
| May 12, 2021 Filed May 13, 2021 16:57 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GiftCommon Stock | 123,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-003461 · primarydocument.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Nick Leschly Irrevocable GST Trust of 2019 Disclosed balance after: 123,000 F1 · kind: This transaction represents a gift of securities by the reporting person's indirectly owned revocable trust account to The Nick Leschly Irrevocable GST Trust of 2019 (the "Irrevocable Trust") designed for the benefit of his spouse and his daughters. The reporting person's brother is the trustee of the Irrevocable Trust. The reporting person disclaims beneficial ownership of the Irrevocable Trust. Read SEC document |
| May 12, 2021 Filed May 13, 2021 16:57 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GiftCommon Stock | 123,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-003461 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Nick Leschly 2001 Trust Disclosed balance after: 45,699 F1 · kind: This transaction represents a gift of securities by the reporting person's indirectly owned revocable trust account to The Nick Leschly Irrevocable GST Trust of 2019 (the "Irrevocable Trust") designed for the benefit of his spouse and his daughters. The reporting person's brother is the trustee of the Irrevocable Trust. The reporting person disclaims beneficial ownership of the Irrevocable Trust. Read SEC document |
| May 03, 2021 Filed May 5, 2021 16:44 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 444 | $30.15 | $13,387.09 |
DisclosureSEC source: 0001562180-21-003231 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,692 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $29.85 to $30.42. The average weighted price was $30.1511. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 16:43 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 444 | $30.21 | $13,411.06 |
DisclosureSEC source: 0001562180-21-002739 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,136 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $30.05 to $30.52. The average weighted price was $30.2051. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 16:50 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 203,355 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001562180-21-002075 · primarydocument.xml · derivative · entry 3 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 203,355 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based criteria that was met on each of January 1, 2013, April 1, 2013, May 1, 2013 and June 24, 2013. The shares underlying these options vested as follows: 1) 25% options vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years, 2) 25% options vested on April 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years, 3) 25% options vested on May 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years, and 4) 25% options vested on July 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 16:50 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 203,355 | $5.50 | $1,118,533.84 |
DisclosureSEC source: 0001562180-21-002075 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 16:46 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 444 | $29.58 | $13,134.36 |
DisclosureSEC source: 0001562180-21-001973 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,225 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $29.31 to $29.92. The average weighted price was $29.5819. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:22 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $28.44 | $0.00 |
DisclosureSEC source: 0001562180-21-001271 · primarydocument.xml · derivative · entry 3 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-02-16 F2 · derivative.exercise_date: This stock option vests over a four-year period at the rate of 25% on 01/04/2022 and then in 36 equal monthly installments thereafter. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:22 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001271 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,669 F1 · security: Restricted stock unit awards vest over a four-year period at the rate of 25% on 01/04/2022, 25% on 01/04/2023, 25% on 01/04/2024, and 25% on 01/04/2025. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 16:04 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 594 | $45.93 | $27,279.63 |
DisclosureSEC source: 0001562180-21-000910 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,669 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $45.55 to $46.25. The average weighted price was $45.9253. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 18:18 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 4,222 | $45.46 | $191,946.90 |
DisclosureSEC source: 0001562180-21-000269 · primarydocument.xml · nonDerivative · entry 3 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,263 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F4 · price: The range in prices for the transaction reported on this line was $45.25 to $45.83. The average weighted price was $45.4635. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 18:18 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 5,873 | $44.76 | $262,867.26 |
DisclosureSEC source: 0001562180-21-000269 · primarydocument.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,485 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F3 · price: The range in prices for the transaction reported on this line was $44.25 to $45.24. The average weighted price was $44.7586. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2021 Filed Jan 8, 2021 18:18 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 333 | $44.95 | $14,969.08 |
DisclosureSEC source: 0001562180-21-000269 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,358 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $44.71 to $45.09. The average weighted price was $44.9522. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 16:48 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 14 | $46.50 | $651.00 |
DisclosureSEC source: 0001562180-20-007077 · primarydocument.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,691 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 16:48 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 430 | $46.19 | $19,861.49 |
DisclosureSEC source: 0001562180-20-007077 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,705 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $45.48 to $46.37. The average weighted price was $46.1895. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 16:04 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 45 | $54.43 | $2,449.53 |
DisclosureSEC source: 0001562180-20-006543 · primarydocument.xml · nonDerivative · entry 3 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,135 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F4 · price: The range in prices for the transaction reported on this line was $54.33 to $54.48. The average weighted price was $54.4340. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 16:04 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 80 | $53.83 | $4,306.18 |
DisclosureSEC source: 0001562180-20-006543 · primarydocument.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,180 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F3 · price: The range in prices for the transaction reported on this line was $53.28 to $54.10. The average weighted price was $53.8272. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 16:04 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 319 | $52.51 | $16,750.28 |
DisclosureSEC source: 0001562180-20-006543 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,260 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $52.25 to $53.08. The average weighted price was $52.5087. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2020 Filed Oct 6, 2020 16:05 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 450 | $52.77 | $23,744.25 |
DisclosureSEC source: 0001562180-20-006302 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,579 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $52.48 to $53.09. The average weighted price was $52.765. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 16:07 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 431 | $58.60 | $25,257.38 |
DisclosureSEC source: 0001562180-20-005918 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,029 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $58.468 to $58.77. The average weighted price was $58.6018. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 16:05 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 112 | $60.98 | $6,829.88 |
DisclosureSEC source: 0001562180-20-005314 · primarydocument.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,460 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F3 · price: The range in prices for the transaction reported on this line was $60.83 to $61.00. The average weighted price was $60.9811. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 16:05 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 332 | $60.32 | $20,025.64 |
DisclosureSEC source: 0001562180-20-005314 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,572 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $59.75 to $60.72. The average weighted price was $60.3182. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 17:19 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 443 | $61.57 | $27,276.75 |
DisclosureSEC source: 0001562180-20-005059 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,904 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $61.27 to $61.88. The average weighted price was $61.5728. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 21:30 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0000899243-20-015645 · doc4.xml · derivative · entry 1 Leschly Nick · CIK 0001578408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-04 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 17:44 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 341 | $64.24 | $21,906.93 |
DisclosureSEC source: 0001562180-20-004288 · primarydocument.xml · nonDerivative · entry 2 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,347 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F3 · price: The range in prices for the transaction reported on this line was $63.76 to $64.30. The average weighted price was $64.2432. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 17:44 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 103 | $63.36 | $6,526.35 |
DisclosureSEC source: 0001562180-20-004288 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,688 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $62.76 to $63.57. The average weighted price was $63.3626. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 16:05 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 11,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-003353 · primarydocument.xml · nonDerivative · entry 1 Leschly Nick · CIK 0001578408 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,791 F1 · security: Restricted stock units for common stock to vest on a monthly basis over a 12-month period with a vesting commencement date on May 1, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.